BBLG Bone Biologics Corporation
USHealthcareAs of 2026-10-08
Why BBLG matters now
Bone Biologics Corporation (BBLG) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.47 with -3.77% on the session and $849.2K in market capitalization; recent performance reads 1-month +15.87% and YTD +0.69%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-766.0K, and EPS of $-0.43. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -98.0%.
The latest indexable market news headline is "Short Interest in Bone Biologics Corp. (NASDAQ:BBLG) Drops By 76.4%" from Defense World.
Additional event context on this page matters because analyst consensus is available with a median target of $—; recent insider activity includes Frelick Jeff filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.56
P/S
0.00
EV/EBITDA
0.89
DCF Value
$4.22
FCF Yield
-98.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-50.4%
ROA
-57.4%
ROIC
-64.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-766.0K | $-0.43 |
| Q4 2025 | $0.00 | $-684.6K | $-0.63 |
| FY 2025 | $0.00 | $-3.1M | $-2.65 |
| Q3 2025 | $0.00 | $-666.7K | $-0.37 |
Analyst Ratings
Consensus
—
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
0.53
Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth. The company is currently advancing the NELL-1/DBX Fusion Device, intended for spinal fusion interventions in skeletally mature individuals experiencing single-level degenerative disc disease within the L4-S1 spinal segments. This versatile platform technology also holds the potential to deliver superior outcomes across a wide spectrum of surgical specialties, including spinal, various orthopedic fields, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Bone Biologics holds a licensing agreement with the UCLA Technology Development Group, which authorizes the development and commercialization of NELL-1 for its spinal fusion applications. The firm was established in 2004 and is based in Burlington, Massachusetts.